Making Optimi commercially viable in 2022 has been our plan since day one, undertaken with three goals in mind.
Completed our 20,000 sq ft EU-GMP psilocybin and functional mushroom cultivation and analytical facilities.
Secured our Health Canada Controlled Drugs and Substances Dealer's Licence to legally produce psychedelic substances.
Grew and delivered our first batch of psilocybin mushrooms for use in clinical trials.
Our ambition is to be the preferred supplier of natural psilocybin and EU-GMP grade synthetic psychedelics for our clients. In December 2021, we developed our Year of Commercialization in response to changes in the psychedelics space.
We are accelerating the shift of capital to areas that have demonstrated the highest potential for returns and in which we have a sustainable advantage through scale – principally our 20,000 sq ft of cultivation and analytical laboratories. We are an early mover acting to secure an underserved segment of the industry aiming to report revenue growth in the medium to long term, with a higher proportion of our revenue from supply agreements and nutraceutical line of functional mushrooms.
New data estimates that the market for psychedelic therapeutics will be valued at $69 billion by 2026, representing a CAGR of 8.2%, indicating the clear growing interest in psychedelic therapeutic drugs.
The figure far surpasses a previous estimate from Research and Markets, which in December projected the industry would grow to a value of $10.75 billion by 2026.
Experts are tapping into MDMA’s effects as part of therapy for severe Post Traumatic Stress Disorder (PTSD), a mental health condition that affects nearly 3.5% of U.S. adults.
The global PTSD treatment market is projected to grow at a CAGR of 4.2% by 2028. Optimi is able to supply pharmaceutical-grade MDMA and psilocybin to meet the growing clinical research demand for this market.
An increasing prevalence of depression and mental disorders, a growing acceptance of psychedelic drugs for treating depression, and post-Covid 19 mental health awareness are critical to industry’s growth.
The global PTSD treatment market is projected to grow at a CAGR of 4.2% by 2028.
Smoking imposes a heavy economic burden throughout the world, particularly in Europe and North America, where the tobacco epidemic is most advanced. Johns Hopkins researchers report 15 study participants taking psilocybin achieved an 80 percent abstinence rate over six months, compared to an approximate 35 percent success rate for patients taking verenicline, which is widely considered to be the most effective smoking cessation drug.
The total economic cost of smoking is estimated at Purchasing Power Parity (PPP) $1852 billion (US$1436 billion), equivalent in magnitude to 1.8% of the world’s annual GDP. The FDA has also cleared Mydecine Innovations Group for a multi-site government funded trial in smoking cessation.
It is projected that by 2026, the global smoking cessation market will be valued at USD $63.99 billion by 2026.
Substance abuse disorder is among the most severe and expensive public health issues across the world. The intensity of the problem is exemplified by the sharp rise in the use of opioid analgesics during the past decade, with the associated significant increase in overdose-related deaths.
According to the latest global estimates, about 36.3 million people, or 13 per cent of the total number of persons who use drugs, suffer from drug use disorders. In 2021, the value of the global substance abuse treatment market stood at US$ 10.2 billion.
The global substance abuse treatment market
treatment market is anticipated to cross USD $23.1 billion by 2031.
An international study led by the University of British Columbia’s Okanagan campus found that adults who used regular microdoses of LSD or psilocybin — also known as magic mushrooms — showed fewer symptoms of anxiety and depression than those who did not. They also reported greater feelings of well-being.
Globally, an estimated 264 million people suffer from depression, one of the leading causes of disability, with many people also suffering from symptoms of anxiety. A recent World Health Organization (WHO)-led study
estimates that depression and anxiety disorders cost the global economy US$ 1 trillion each year in lost productivity.
The global anxiety and depression treatment market value is predicted to increase at a 3.3% CAGR from USD $17.7 billion in 2021 to USD $24.4 billion by 2031.
Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing services, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are creating new revenue pockets in the drug discovery services market.
In 2021, the lead identification & candidate optimization segment dominated the market. It is one of the most critical processes in drug discovery. Small molecules dominated the market in 2021, and the segment is also projected to register a high CAGR during the forecast period.
The growth can be attributed to the government initiatives to forge alliances with U.S. pharmaceutical companies.
Drug discovery is a costly and lengthy process, which has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs). The global drug discovery outsourcing market size is expected to reach USD $6.3 billion by 2030 at a CAGR of 7.4%.
“Establishing Optimi’s presence in the psychedelic market begins with trust, which we believe we have earned through our in-house expert research and world-class advisory team, and by setting the gold standard in GMP compliance.”
– JJ Wilson, Optimi Co-Founder
Our Year of Commercialization was designed to make Optimi commercially viable in both the short and long-term, through two significant milestones: the completion of our 20,000 square feet of EU-GMP mushroom cultivation and analytical facilities, and the sale of our first harvest.
We continue to maintain a strong capital, funding, and liquidity position with a diversified business model. We take a conservative approach to credit risk and liquidity management.
With our main capital expenditure completed, our capital base supports our ability to invest in business growth, and meet current and future regulatory requirements.
Optimi Health Corp.
330 – 1122 Mainland Street, Vancouver, BC V6B 5L1
Legal Counsel: Norton Rose Fulbright
Auditor: Smythe CPA
Transfer Agent: Endeavor Trust
Corporate Visibility & Investor Relations: Kydder Group
Trading Symbol: CSE: OPTI | OTC:OPTHF |
CUSIP Number: 68405H100
ISIN Number: CA68405H1001
Issued & Outstanding: (30/06/2022) 80,451,883
Incorporated: BC / May 27, 2020
Year End: September 30th
Products do not contain psilocybin